[ad_1]
Vaccine for COVID-19: New details on experimentation leaked Modern.
In the rush to treatment that is especially accelerated in U.S, haunted by the frenzy of Triumph, the company proves to keep up.
With the goal of increasing confidence in a reliable vaccine that is ready as soon as possible, Moderna has revealed data on the next stages of the trial.
A transparency operation that wants above all to create a climate of clarity and optimism about the long-awaited vaccine, not only in the United States.
Modern: details on vaccine testing
Before starting the investors meeting on Thursday, September 17, Modern stated that enlisted men were already involved in the testing phase of their vaccine 25,296 Of the 30,000 planned people, more than 10,000 have already received two doses of the vaccine.
The pharmaceutical group wanted to define officially and publicly all the details about how the tests will be carried out on volunteers. A data monitoring committee will preliminarily review the efficacy results after 53 participants contract the coronavirus and again after 106 cases have been reached. The final analysis will take place after 151 cases.
CEO Stephane Bancel explained that:
“We worked for nine months to try to stop this virus by putting a vaccine on the market. We want to make sure that people generally trust vaccines by being transparent. “
The test of Modern It will be considered positively, with the treatment evaluated as very effective, only if in the first analysis the reduction of COVID-19 cases is equal to 74% or more.
If the vaccine will have a more modest impact (60% of cases reduced), the study may need to continue even before generating clear results, depending on the testing protocol.
The shares rose 2% to $ 70.20 in pre-market trading in New York. They have more than tripled since the beginning of the year.
The new vaccine predictions
Chief Executive Officer Bancel said the most likely scenario is that Moderna’s vaccine could provide preliminary efficacy data in November.
Achieving the same goal in October is unlikely.
In general, the expected scenario is less optimistic than expected Triumph. Moderna leaders, in fact, estimate that it is highly unlikely that everyone in the country will be vaccinated by the end of the first quarter of 2021. We will have to wait at least until the second part of next year.
The three vaccines in the most advanced testing phase are based on recent technologies, which means that companies have had to create new production capacity.
Meanwhile, Moderna wishes to specify on her own vaccine No shutdowns have been imposed in the name of safety, as was the case with AstraZeneca testing days ago, now resumed.
